Cholangiocarcinoma, Hilar
Conditions
Brief summary
Hilar cholangiocarcinoma is a highly aggressive malignancy, and surgical resection remains the only potentially curative treatment. Due to the frequent involvement of major vascular structures, vascular resection is increasingly performed to achieve negative surgical margins; however, its impact on survival and postoperative outcomes remains controversial. This retrospective study aims to evaluate the association between vascular resection and clinical outcomes, including survival and postoperative outcomes, in patients with hilar cholangiocarcinoma undergoing curative-intent surgery.
Interventions
OTHERNo Intervention: Observational Cohort
This is an observational study. No intervention is assigned.
Sponsors
Yongjun Chen
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Inclusion criteria
* Patients who underwent surgical treatment at the Department of Hepatobiliary and Pancreatic Surgery of our hospital between January 2010 and December 2024, including those with or without concomitant vascular resection. * Pathologically confirmed diagnosis of hilar cholangiocarcinoma after surgery. * Complete clinical and follow-up data available for outcome analysis.
Exclusion criteria
* Patients with distant metastasis or who underwent only palliative or exploratory surgery. * Patients diagnosed preoperatively or intraoperatively with other types of biliary malignancies not located at the hilar region. * Patients with incomplete medical records or missing key clinical or follow-up data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative Complications Grade II or Higher (Clavien-Dindo ≥ II) | Within 30 days after surgery | Postoperative complications within 30 days after surgery will be assessed and classified according to the Clavien-Dindo classification system. Grade II or higher complications are defined as complications requiring pharmacological treatment, blood transfusion, interventional procedures, reoperation, intensive care management, or resulting in death. |
| Overall Survival (OS) | From surgery to death or last follow-up (up to 5 years) | Time from the date of curative-intent surgery to death from any cause or last follow-up. Patients who are alive at the last follow-up will be censored. Survival data will be collected from medical records and follow-up visits. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Perioperative Mortality | 30 days after surgery or during hospitalization | Death occurring within 30 days after surgery or during the index hospitalization, whichever occurs later. |
| Length of Postoperative Hospital Stay | From the date of surgery to hospital discharge, assessed up to 90 days. | Number of days from the date of surgery to hospital discharge. |
| Intraoperative Blood Loss | During surgery | Estimated blood loss recorded in the operative report, measured in milliliters. |
| Disease-Free Survival (DFS) | From surgery to tumor recurrence, metastasis, death, or last follow-up (up to 5 years) | Time from surgery to tumor recurrence, metastasis, death from any cause, or last follow-up, whichever occurs first. |
Outcome results
None listed